Mentoring in Advanced mHealth Technologies and Machine Learning for HIV/Drug Abuse Research

摘要 续签我的以患者为中心的研究中期研究员奖(K24)将使我继续我的强大努力 旨在成功地进行原创调查和指导，以产生移动技术方面的研究能力 改善健康(MHealth)。最初的K24对我的学员的影响是惊人的。自最初的K24获奖以来， 我的近24名学员，其中70%是女性或少数族裔，曾在NIH资助的研究中担任PI(根据K，R， 或贷款偿还计划机制)。K24对我自己的研究产生了巨大的影响。自2014年以来，我 曾在6个联邦资助的奖项上担任首席研究员(PI)：1)NIDA新资助的4年期R01；2)1 R56 来自NIDA；3)来自NIDA的一个两年期R01；4)来自NIDA的一个4年期R01；5)来自NIDA的My K24；以及6)一个新资助的 DARPA研究奖，为期4年。此外，我还获得了威廉·J·富布赖特到马来西亚的外国奖学金。作为我的K24 进化了，我的研究重点也变了。我的总体研究目标是花足够的时间调查NEXT的使用情况 下一代(“NextGen”)技术、隐形生物传感以及药物滥用和艾滋病毒研究中的机器学习。我的 第一个研究项目，Virya，使用具有隐形生物传感和机器学习的“数字表型”来识别急性疼痛 艾滋病毒+阿片类药物个人的恶化，这是一个有问题的阿片类药物使用风险的人群。第二个研究项目 利用移动技术诊断吸食大麻的艾滋病毒携带者中的新冠肺炎感染，这本身就是一个影响很大的话题。 最后，R01资助的MyTPill项目比较了NextGen技术的非侵入性可食用生物传感器，这些传感器提供了 生动、无可争辩的药物摄取措施。NextGen研究发现变成了商业产品，但这 将新发现引入医疗保健经济的过程仍然非常陌生-但越来越重要- 致学院派临床医生和科学家。因此，我的职业发展活动的目标是学习如何 协调监管流程、FDA批准、估值、风险投资、合同和知识产权。因为 关于研究成果商业化对学术事业的健康和可持续性日益重要的问题，我的 本K24课程的总体指导目标是培养不仅具备执行严格下一代技术的研究人员 移动健康研究，也是为了将NIH资助的大量移动健康研究扩展到医疗保健经济。我的导师 该方法包含了促成我最初的K24课程成功的几个组成部分：为学员的 早期调查；出色的机构支持；高质量学员的几个转介来源；以及知名的联合 导师，他们将帮助我建立一个渠道，指导学生已经上升到成功的学术 职业生涯开始了。这项提议的K24更新，其重点是下一代技术、隐形生物传感和机器 学习，与NIH的任务高度相关，因为从药物滥用和艾滋病毒研究中吸取的教训是 直接适用于常见、难治、昂贵病症患者的护理。

Abstract Renewal of my Midcareer Investigator Award in Patient-Oriented Research (K24) will allow me to continue my strong efforts directed toward successful original investigations and mentoring to generate research capacity in mobile technologies to improve health (mHealth). The impact of the initial K24 on my mentees has been striking. Since award of the initial K24, nearly two dozen of my mentees, 70% of whom are women or minorities, have been PI on NIH funded studies (under K, R, or Loan Repayment Program mechanisms). The impact the K24 on my own research has been substantial. Since 2014, I have been Principal Investigator (PI) on six federally funded awards: 1) one newly funded 4-year R01 from NIDA; 2) one R56 from NIDA; 3) one two-year R01 from NIDA; 4) one 4-year R01 from NIDA; 5) my K24 from NIDA; and 6) one newly funded 4-year DARPA research award. In addition, I received a William J Fulbright Foreign Scholarship to Malaysia. As my K24 evolved, so has my research focus. My overall research objective is to devote sufficient time to investigate use of next generation (“NextGen”) technologies, invisible biosensing, and machine learning in substance abuse and HIV research. My first research project, Virya, uses “digital phenotyping” with invisible biosensing and machine learning, to identify acute pain exacerbations in HIV+ individuals on opioids, a population at risk for problematic opioid use. The second reseach project uses mobile technologies to diagnose Covid-19 infection in HIV+ persons who inhale cannabis, itself a high-impact topic. Finally, the R01-funded MyTPill project compares the NextGen technology of unobtrusive ingestible biosensors that provide vivid, indisputable measures of medication ingestion. NextGen research discoveries become commercial products, but this process of introducing new discoveries into the healthcare economy remains deeply unfamiliar—yet increasingly important— to academic clinician-scientists. The objective of my Career Development Activities, therefore, involves learning how to navigate regulatory processes, FDA approvals, valuations, venture capital, contracts and intellectual property rights. Because of the growing importance of commercialization of research findings to the health and sustainability of academic careers, my overall mentoring objective of this K24 is to develop researchers who not only have the skills to conduct rigorous NextGen mHealth studies, but also to extend the mass of NIH-funded mHealth research into the healthcare economy. My mentoring approach incorporates several components that contributed to the success of my initial K24: dedicated funding for mentee’s early investigations; outstanding institutional support; several sources of referral of high-quality mentees; and renowned co- mentors who will help me establish a pipeline of mentees that have risen to that “cutting edge” where successful academic careers begin. This proposed K24 renewal, with its focus on NextGen technologies, invisible biosensing, and machine learning, is highly relevant to NIH’s mission because the lessons learned from this substance abuse and HIV research are directly applicable to the care of patients with common, intractable, and expensive conditions.